Myocardial infarction: Is evidence-based medicine the best?

Lancet

Volumn 359, Issue 9316, 2002, Pages 1515-1516

  Julian, D G ^a   Norris, R M ^a  

^a NONE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; FIBRINOLYTIC AGENT; STREPTOKINASE;

ANALGESIA; CARDIOGENIC SHOCK; CLINICAL TRIAL; CONVALESCENCE; DISEASE COURSE; DISEASE SEVERITY; EVIDENCE BASED MEDICINE; FIBRINOLYSIS; HEART FAILURE; HEART INFARCTION; HEART VENTRICLE FIBRILLATION; HOSPITAL DISCHARGE; HUMAN; INTERMETHOD COMPARISON; MEDICAL CARE; META ANALYSIS; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RESUSCITATION; SHORT SURVEY; SMOKING CESSATION; SURVIVAL TIME; TREATMENT OUTCOME;

EID: 0037181678     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(02)08419-2     Document Type: Note

References (7)

1. Effect of time from onset to coming under care on fatality of patients with acute myocardial infarction: Effect of resuscitation and thrombolytic treatment
2. A new performance indicator for acute myocardial infarction
3. Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients
4. Early thrombolytic treatment in acute myocardial infarction: Reappraisal of the Golden Hour
5. Translation of clinical trials into practice: A European population-based study on the use of thrombolysis for acute myocardial infarction
6. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction
7. Acute myocardial infarction